Sign up to access all our data and the evidence and analysis underlying our overall scores. Once you've created an account, we'll get in touch with further details:
Sign Up
| Overall Assessment |
Analysis |
Score |
|
Limited
|
Zimmer Biomet provides only a limited indication of its lobbying governance, primarily through a public commitment to align its engagement activities with global climate objectives, but it does not disclose any formal processes or oversight structures for managing or monitoring those activities. Zimmer Biomet affirms “Yes” when asked if it has a “public commitment or position statement to conduct your engagement activities in line with the goals of the Paris Agreement,” and states that “Zimmer Biomet is committed to participating constructively and responsibly in the public policy process.” However, we found no evidence of a specific individual or formal body overseeing lobbying alignment, no described policy or review procedure to ensure direct or indirect lobbying supports the company’s climate targets, and no mechanism for evaluating trade associations against its climate commitments.
View Sources
|
D
|
| Overall Assessment |
Analysis |
Score |
|
None
|
Zimmer Biomet offers detail on how it interacts with U.S. federal and state officials and the policy areas it prioritises in the healthcare space, but it provides no information indicating that it has lobbied on any climate-related laws, regulations or standards. The disclosures that are available focus exclusively on issues such as the “Medical Device User Fee Amendments (MDUFA),” “payment and reimbursement policies,” and “trade policy initiatives that seek to improve access to medical devices,” none of which are climate or energy-transition measures. Although the company notes that its Government Affairs office and external firms engage the U.S. Congress, the Executive Branch and state governments, these descriptions are not connected to climate policy. Likewise, its stated objectives—supporting “tax policies that support innovation and global competitiveness” and “payment and reimbursement policies that ensure stability and access for patients” —do not relate to climate outcomes. As a result, we found no evidence of transparency regarding climate-specific policies lobbied, the mechanisms used to influence climate legislation, or the climate outcomes the company seeks.
|
E
|